Mindy Clyne

Mindy Clyne

Auto-generated profile, based on publicly available information

Mindy Clyne

Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2002 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Julian LittleJulian Little
Julian Little
LBLinda Bradley
Linda Bradley
MBMolly S. Bray
Molly S. Bray
MCMindy Clyne
Mindy Clyne
JDJanice Dorman
Janice Dorman
CWClarice R. Weinberg
Clarice R. Weinberg
The recent completion of the first draft of the human genome sequence and advances in technologies for genomic analysis are generating tremendous opportunities for epidemiologic studies to evaluate the role of genetic variants in human disease. Many methodological issues apply to the investigation of variation in the frequency of allelic variants of human genes, of the possibility that these influence disease risk, and of assessment of the magnitude of the associated risk. Based on a Human Genome Epidemiology workshop, a checklist for reporting and appraising studies of genotype prevalence and studies of gene-disease associations was developed. This focuses on selection of study subjects, analytic validity of genotyping, population stratification, and statistical issues. Use of the checklist should facilitate the integration of evidence from these studies. The relation between the checklist and grading schemes that have been proposed for the evaluation of observational studies is discussed. Although the limitations of grading schemes are recognized, a robust approach is proposed. Other issues in the synthesis of evidence that are particularly relevant to studies of genotype prevalence and gene-disease association are discussed, notably identification of studies, publication bias, criteria for causal inference, and the appropriateness of quantitative synthesis.

14 December 2017 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
MKMuin J Khoury
Muin J Khoury
MBM. Scott Bowen
M. Scott Bowen
MCMindy Clyne
Mindy Clyne
WDW. David Dotson
W. David Dotson
MGMarta L. Gwinn
Marta L. Gwinn
WYWei Yu
Wei Yu
In this paper, we review the evolution of the field of public health genomics in the United States in the past two decades. Public health genomics focuses on effective and responsible translation of genomic science into population health benefits. We discuss the relationship of the field to the core public health functions and essential services, review its evidentiary foundation, and provide examples of current US public health priorities and applications. We cite examples of publications to illustrate how Genetics in Medicine reflected the evolution of the field. We also reflect on how public-health genomics is contributing to the emergence of “precision public health” with near-term opportunities offered by the US Precision Medicine (AllofUs) Initiative.

15 April 2003 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Julian LittleJulian Little
Julian Little
MKMuin J Khoury
Muin J Khoury
LBLinda Bradley
Linda Bradley
MCMindy Clyne
Mindy Clyne
MGMarta Gwinn
Marta Gwinn
PYPaula Yoon
Paula Yoon
Received for publication February 19, 2003; accepted for publication February 27, 2003.

1 February 1989
Verified
Journal Article
Closed access
IBI BALAZS
I BALAZS
MBM BAIRD
M BAIRD
MCM CLYNE
M CLYNE
EME MEADE
E MEADE

9 January 2014 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
MCMindy Clyne
Mindy Clyne
SSSheri D. Schully
Sheri D. Schully
WDWilliam David Dotson
William David Dotson
Michael P DouglasMichael P Douglas
Michael P Douglas
MGMarta Gwinn
Marta Gwinn
MKMuin J. Khoury
Muin J. Khoury
Purpose: The dizzying pace of genomic discoveries is leading to an increasing number of clinical applications. In this report, we provide a method for horizon scanning and 1 year data on translational research beyond bench to bedside to assess the validity, utility, implementation, and outcomes of such applications. Methods: We compiled cross-sectional results of ongoing horizon scanning of translational genomic research, conducted between 16 May 2012 and 15 May 2013, based on a weekly, systematic query of PubMed. A set of 505 beyond bench to bedside articles were collected and classified, including 312 original research articles; 123 systematic and other reviews; 38 clinical guidelines, policies, and recommendations; and 32 articles describing tools, decision support, and educational materials. Results: Most articles (62%) addressed a specific genomic test or other health application; almost half of these (n = 180) were related to cancer. We estimate that these publications account for 0.5% of reported human genomics and genetics research during the same time. Conclusion: These data provide baseline information to track the evolving knowledge base and gaps in genomic medicine. Continuous horizon scanning of the translational genomics literature is crucial for an evidence-based translation of genomics discoveries into improved health care and disease prevention. Genet Med 16 7, 535–538.

1 February 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
GNGila Neta
Gila Neta
MCMindy Clyne
Mindy Clyne
DCDavid A. Chambers
David A. Chambers
Background: To ensure investment in cancer research reaches populations who can benefit, the NCI has funded implementation science grants since the Dissemination and Implementation Research in Health (DIRH) funding opportunities launched in 2006. We analyzed NCI-funded DIRH grants to provide a snapshot of implementation science conducted across the cancer care continuum and highlight areas ripe for exploration. Methods: NCI-funded DIRH grants between fiscal years 2006 and 2019 were identified using the iSearch database. Two coders classified each grant by topic, populations studied, intervention and setting characteristics, strategies tested, study designs and methods used, and outcomes measured. Results: Seventy-one grants were awarded addressing cancer prevention (n = 33), screening (n = 33), diagnosis (n = 4), treatment (n = 9), and/or survivorship (n = 11). Colorectal (n = 20), breast (n = 15), and cervical (n = 11) were the most studied cancers. Most grants focused on delivery of guidelines (n = 36) or behavioral change interventions (n = 18) in health care settings (n = 47), studying implementation processes (n = 37) and/or testing implementation strategies (n = 43) using experimental (n = 35) and quasi-experimental (n = 6) designs. Few studied sustainability (n = 7), scale-up (n = 2), deimplementation (n = 4), measure development (n = 6), or policy-level implementation (n = 6). Conclusions: Current funding suggests researchers are studying implementation of cancer control interventions across the care continuum. However, research gaps remain in strategies for sustainability, scale-up, and deimplementation. More emphasis is needed on cancer treatment and survivorship. Additional focus on policy implementation and measure development is warranted. Impact: Understanding the breadth of NCI-funded implementation science can inform future efforts to build the knowledge base on how to improve dissemination and implementation of evidence in cancer control.